Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles from US Central Zone
Based on 2,139 articles published since 2008
||||

These are the 2139 published articles about Parkinson Disease that originated from US Central Zone during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015

Odin, P / Ray Chaudhuri, K / Slevin, J T / Volkmann, J / Dietrichs, E / Martinez-Martin, P / Krauss, J K / Henriksen, T / Katzenschlager, R / Antonini, A / Rascol, O / Poewe, W / Anonymous2260838. ·Department of Neurology, Lund University Hospital, 221 85 Lund, Sweden; Klinikum-Bremerhaven, D-27574 Bremerhaven, Germany. Electronic address: per.odin@med.lu.se. · King's College London, and National Parkinson Foundation Centre of Excellence, Dept of Neurology, King's College Hospital, London, UK. · Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 South Limestone Street, Lexington, KY 40536-0284, USA. · Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany. · Department of Neurology, Oslo University Hospital and University of Oslo, N-0424 Oslo, Norway. · National Center for Epidemiology and CIBERNED, ISCIII, Avenida Monforte de Lemos 5, 28029 Madrid, Spain. · Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. · University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400 København, NV, Denmark. · Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost - Donauspital, 1220 Wien Langobardenstraße 122, Austria. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. · Clinical Investigation Center 1436 and Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France; Clinical Investigation Center 1436 and Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France. · Innsbruck Medical University/University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. ·Parkinsonism Relat Disord · Pubmed #26233582.

ABSTRACT: Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

2 Editorial Managing anxiety in Parkinson's disease: the role of nonpharmacological strategies. 2018

Rocha, Natalia P / Teixeira, Antonio L. ·Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica, Belo Horizonte MG, Brasil. · The University of Texas Health Science Center at Houston, McGovern Medical School, Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, Houston, Texas, USA. ·Arq Neuropsiquiatr · Pubmed #30231120.

ABSTRACT: -- No abstract --

3 Editorial Cerebrospinal fluid levels of alpha-synuclein in PARKINSON'S disease: Another long and winding road. 2018

Markopoulou, Katerina / Compta, Yaroslau. ·Movement Disorders Section, Department of Neurology, NorthShore University HealthSystem, Chicago, Evanston, USA; University of Chicago, Pritzker School of Medicine, Chicago, IL, USA. · Parkinson's Disease and Movement Disorders Unit, Neurology Service, ICN, Hospital Clínic, IDIBAPS, CIBERNED, Barcelona, Catalonia, Spain; Physiology Unit, Department of Biomedicine, Institut de Neurociències, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: ycompta@clinic.cat. ·Parkinsonism Relat Disord · Pubmed #29548634.

ABSTRACT: -- No abstract --

4 Editorial Take care to identify apathy in idiopathic rapid eye movement sleep behavior disorder. 2018

St Louis, E K. ·Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic and Foundation, Rochester, MN, USA. ·Eur J Neurol · Pubmed #29528541.

ABSTRACT: -- No abstract --

5 Editorial Immunologic treatment of Parkinson's disease. 2018

Jankovic, Joseph. ·Distinguished Chair in Movement Disorders, Director, Parkinson's Disease Center & Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A; Houston, TX 77030-4202, USA. ·Immunotherapy · Pubmed #29260621.

ABSTRACT: -- No abstract --

6 Editorial The future burden of Parkinson's disease. 2018

Rocca, Walter A. ·Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. · Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. ·Mov Disord · Pubmed #28782890.

ABSTRACT: -- No abstract --

7 Editorial Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? 2017

Goetz, Christopher G. ·Rush University Medical Center, Chicago, Illinois, USA. ·Mov Disord · Pubmed #29119602.

ABSTRACT: -- No abstract --

8 Editorial What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease. 2017

Standaert, David G. ·Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. ·Mov Disord · Pubmed #29068500.

ABSTRACT: -- No abstract --

9 Editorial Can lifestyle modification slow progression of Parkinson disease? 2017

Hedera, Peter / Davis, Thomas L. ·From the Department of Neurology, Vanderbilt University Medical Center, Nashville, TN. peter.hedera@vanderbilt.edu. · From the Department of Neurology, Vanderbilt University Medical Center, Nashville, TN. ·Neurology · Pubmed #28972193.

ABSTRACT: -- No abstract --

10 Editorial Virtually reducing fall risk in Parkinson disease. 2017

Moreau, Caroline / Barton, Brandon R / Devos, David. ·From the Service de Neurologie (C.M., D.D.) and Services de Pharmacologie and Médicale (D.D.), LICEND COEN Center, Université de Lille, CHU de Lille, INSERM UMRS_1171, France · Department of Neurological Sciences (B.R.B.), Rush University Medical Center · and Neurology Service (B.R.B.), Jesse Brown VA Medical Center, Chicago, IL. ·Neurology · Pubmed #28954881.

ABSTRACT: -- No abstract --

11 Editorial Understanding Parkinson disease in sub Saharan Africa: A call to action for the international neurologic community. 2017

Bower, James H. ·Department of Neurology, Mayo Clinic, Rochester, MN, USA. ·Parkinsonism Relat Disord · Pubmed #28528803.

ABSTRACT: -- No abstract --

12 Editorial What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. 2017

Kordower, Jeffrey H. ·Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, 60612. · The Van Andel Research Institute, Grand Rapids Michigan, 49503. ·Mov Disord · Pubmed #28425143.

ABSTRACT: -- No abstract --

13 Editorial Orthostatic hypotension, cognition, and Parkinson disease: Dumbing down by standing up. 2017

Boylan, Laura S / Messinis, Lambros. ·From the Department of Neurology (L.S.B.), New York University School of Medicine, New York · Department of Neurology (L.S.B.), Essentia Health, Duluth, MN · Department of Neurology (L.S.B.), Bellevue Hospital, New York, NY · and Neuropsychology Section, Department of Neurology (L.M.), University of Patras Medical School, Greece. ·Neurology · Pubmed #27903812.

ABSTRACT: -- No abstract --

14 Editorial Solutions for improving communication with Parkinson's disease patients. 2016

Holtgraves, Thomas. ·Department of Psychological Science, Ball State University, Muncie, IN 47306, USA. ·Neurodegener Dis Manag · Pubmed #27827553.

ABSTRACT: -- No abstract --

15 Editorial Fetal grafts for Parkinson's disease: Decades in the making. 2016

Kordower, Jeffrey H / Olanow, C Warren. ·Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612; Van Andel Institute, Grand Rapids, MI 49503; jkordowe@rush.edu. · Department of Neurology, Mt. Sinai School of Medicine, New York, NY 10029; Department of Neuroscience, Mt. Sinai School of Medicine, New York, NY 10029. ·Proc Natl Acad Sci U S A · Pubmed #27247420.

ABSTRACT: -- No abstract --

16 Editorial Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis. 2016

Calabresi, Paolo / Standaert, David G / Chiasserini, Davide / Parnetti, Lucilla. ·Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy. · IRCCS Fondazione Santa Lucia, Rome, Italy. · Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. ·Mov Disord · Pubmed #27245116.

ABSTRACT: -- No abstract --

17 Editorial Identification of bona-fide LRRK2 kinase substrates. 2016

West, Andrew B / Cookson, Mark R. ·Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama, USA. · Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. ·Mov Disord · Pubmed #27126091.

ABSTRACT: -- No abstract --

18 Editorial Circuits and Circuit Disorders: Approaches to Neuromodulation. 2015

Rosenberg, Roger N. ·Department of Neurology, University of Texas Southwestern Medical Center, Dallas2Editor, JAMA Neurology. ·JAMA Neurol · Pubmed #26409204.

ABSTRACT: -- No abstract --

19 Editorial Cognitive decline in Parkinson disease: How steep and crowded is the slope? 2015

Hershey, Linda A / Peavy, Guerry M. ·From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City · and the Department of Neurosciences (G.M.P.), University of California, San Diego. ·Neurology · Pubmed #26362284.

ABSTRACT: -- No abstract --

20 Editorial Preface. 2015

Poewe, Werner / Goetz, Christopher G. ·Innsbruck Medical University, Austria. · Rush University Medical Center, Chicago, Illinois. ·Mov Disord · Pubmed #26301896.

ABSTRACT: -- No abstract --

21 Editorial MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease? 2015

Öz, Gülin. ·Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA. ·Mov Disord · Pubmed #26184363.

ABSTRACT: -- No abstract --

22 Editorial Clinical Determinants of Progression of Parkinson Disease: Predicting Prognosis by Subtype. 2015

Schiess, Mya Caryn / Suescun, Jessika. ·Department of Neurology, The University of Texas Medical School at Houston, Houston. ·JAMA Neurol · Pubmed #26075915.

ABSTRACT: -- No abstract --

23 Editorial Smoking and Parkinson disease: where there is smoke there may not be fire. 2014

Hershey, Linda A / Perlmutter, Joel S. ·From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City · and Departments of Neurology, Radiology, and Neurobiology, and Programs of Physical Therapy and Occupational Therapy (J.S.P.), Washington University, St. Louis, MO. ·Neurology · Pubmed #25217061.

ABSTRACT: -- No abstract --

24 Editorial Emergence of deglutology: a transdisciplinary field. 2014

Babaei, Arash / Shaker, Reza. ·Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin. ·Clin Gastroenterol Hepatol · Pubmed #25194805.

ABSTRACT: -- No abstract --

25 Editorial Peripheral and cognitive signs: delineating the significance of impaired catecholamine metabolism in Parkinson's disease progression. 2014

Salvatore, Michael F / Disbrow, Elizabeth A / Emborg, Marina E. ·Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA. · Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA. · Wisconsin National Primate Research Center and Department of Medical Physics, University of Wisconsin, Madison, Wisconsin, USA. ·J Neurochem · Pubmed #25039428.

ABSTRACT: -- No abstract --

Next